AIRO Lung

BREAKING: A new randomized trial demonstrates the benefit of SBRT for patients with EGFR+ stage IV NSCLC. It demonstrates both PFS and OS benefits (n=62). 🇨🇳 #radonc @EGFRResisters @jillfeldman4 thegreenjournal.com/article/S0167-…

Final Results CC001 Addition HA to WBRT+memantine · Prevented cognitive failure (HR 0.74,p=0.016) · Less symptom burden 6 & 12 mos · Less symptom interference 6 & 12 mos · Fewer cognitive symptoms overtime · NO diff OS, PFS, Toxicity redjournal.org/article/S0360-…

Nn M

The Multidisciplinary Approach in Stage III Non-Small Cell Lung Cancer over Ten Years: From Radiation Therapy Optimisation to Innovative Systemic Treatments mdpi.com/1957474 #mdpicancers via @Cancers_MDPI

🚨@OncoAlert new meta-analysis of SRS vs WBRT in pts with small cell lung cancer in @TheLancetOncol suggesting equitable survival outcomes #radonc #lcsm #btsm thelancet.com/journals/lanon…

Delighted to share our systematic review of heart dose - More stringent IMRT❤️sparing planning objectives needed - Consensus on contouring and Dose Volume Constraints is lacking - Dose parameters reported for substructures vary substantially pubmed.ncbi.nlm.nih.gov/35577022/

I Venerdì di AIRO: webinar su nuove evidenze e temi scottanti in radio-oncologia toracica nel trattamento del NSCLC stadio III 8 aprile 14.30-16.30 ecm.radioterapiaitalia.it/front/single/22 @AndrearicFili @PaoloBorghetti2 @ALESSIOBRUNI10 @giuliapasello @serenabadellino @stefanovagge @airo_young

A very important topic that deserves future strategies to improve this scenario! @JTOonline @IASLC @myESMO @AIOMtweet @AIRO80327989 @finn_corinne @LungCancer_HU @LungCancer_H @ASCO @OncoPolmoneIEO

Very interesting case!

A very important theme!

PORT o non PORT? La RT postoperatoria per NSCLC pN2 non ha mostrato un vantaggio in DFS come era atteso. Rimane un'opzione per resezione incompleta o per estensione extracapsulare #LungART

Longer follow-up shows even greater impact of #radonc SABR for oligometastases in @drdavidpalma's SABR-COMET trial @caro_acro_ca #CARO2020 #CAROVSM2020. Now 22 month increase in overall survival (possibly also driven by post-trial SABR). See @asco_pubs ascopubs.org/doi/10.1200/JC…

Read this study from #JTOCRR Issue 3 and the #COVID19 collection by Fu et al., examining the real-world scenario of patients with lung cancer during the COVID-19 pandemic in China. jtocrr.org/article/S2666-… @IASLC @OncologyAdvance #openaccess #LCSM

#ESMO20 excellent discussion of LungART trial illustrating the reasons behind the lack of statistical advantage of PORT in pN2 resected NSCLC with a PFS HR of 0.85 (0.61-1.07)

LungART: no sign 3yr DFS improvement (43.8 to 47.1%) for adj RT in pN2 IIIa #NSCLC. Importantly no OS benefit, but reduced local relapse (46.1 to 25%), but incrsed death (5.3 to 14.6%); Excess deaths in RT arm mainly from cardio-pulmonary tox, more new cancers @OncoAlert #ESMO20

Pubblicato oggi sul giornale New England Journal of Medicine il lavoro in esteso dello studio clinico ADAURA, una pietra miliare nel trattamento del tumore del polmone. Le nostre congratulazioni al Prof de Marinis, autore di questo importante lavoro @IEOufficiale

Very interesting theory... @JTOonline

AURA3 Fails To Demonstrate OS Benefit For Osimertinib: Osimertinib does not significantly extend overall survival compared with platinum–pemetrexed for previously treated advanced non-small-cell lung #cancer pts with an EGFR T790M mutation ow.ly/J6Dv50BifnR #lcsm #nsclc

Very interesting real world analysis! @IASLC @AIOMtweet @JTOonline

In an article published in @JTOonline Dr. Myung-Ju Ahn et al. discuss Osimertinib Improves Overall Survival in Patients With EGFR-Mutated NSCLC With Leptomeningeal Metastases Regardless of T790M Mutational Status. ow.ly/BIZt50AYQaF #LCSM #LungCancer #Oncology